Orphazyme to discuss NPC rejection with FDA in mid-October

Denmark-based biotech company Orphazyme has planned a meeting with the US Food and Drug Administration to discuss the rejection it received in June.

Photo: Nikolaj Skydsgaard/REUTERS / X07081

Progress appears to have been made in Orphazyme's ongoing battle to get its key candidate, arimoclomal, approved as a treatment for Niemann-Pick Type C (NPC) in the US.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs